Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr Van Oekelen on the Role of S100A8/A9 in Promoting T-Cell Exhaustion in Multiple Myeloma

September 24th 2025

Oliver Van Oekelen, MD, PhD, discusses how S100A8/A9 in promotes T-cell exhaustion and limits responses to bispecific antibody therapy in multiple myeloma.

Dr Raab on Teclistamab-Based Regimens in Newly Diagnosed Multiple Myeloma

September 24th 2025

Marc S. Raab, MD, discusses teclistamab for the treatment of patients with newly diagnosed multiple myeloma.

SCOPE Score Validated as Predictive Tool for Outcomes With BCMA CAR T-Cell Therapy in R/R Multiple Myeloma

September 24th 2025

The SCOPE score was predictive of response, toxicity, and survival outcomes in patients with relapsed/refractory myeloma receiving BCMA CAR T-cell therapy.

Myeloma Experts Summarize Key Themes From the 22nd Annual IMS Meeting and Exposition

September 23rd 2025

OncLive heard from myeloma experts about the biggest developments in the field at the 22nd Annual International Myeloma Society Meeting and Exposition.

IberDd Demonstrates Positive Topline Efficacy in Relapsed/Refractory Multiple Myeloma

September 23rd 2025

IberDd improved MRD negativity rates vs DVd in patients with relapsed/refractory multiple myeloma.

Linvoseltamab Adds Highly Effective Option in Later-Line Multiple Myeloma

September 23rd 2025

Hans Lee, MD; and Nisha Joseph, MD, discuss the FDA approval of linvoseltamab for the treatment of patients with relapsed/refractory multiple myeloma.

Isa-VRd Displays High VGPR or Better Rate in Transplant-Ineligible Newly Diagnosed Multiple Myeloma

September 22nd 2025

Isa-VRd produced a VGPR or better rate of 87.8% in transplant-ineligible newly diagnosed multiple myeloma.

Five Under 5: Top Oncology Videos for the Week of 9/14

September 21st 2025

The top 5 OncLive TV videos of the week cover insights in lung cancer, multiple myeloma, and ovarian cancer.

Sonrotoclax Plus Dexamethasone Generates Early Efficacy in R/R Myeloma

September 21st 2025

Sonrotoclax plus dexamethasone was well tolerated and produced early efficacy signals in relapsed/refractory multiple myeloma with t(11;14).

BKd Produces Robust Responses in Relapsed/Refractory Multiple Myeloma

September 20th 2025

Belantamab mafodotin plus carfilzomib and dexamethasone was active in patients with relapsed/refractory multiple myeloma.

Belantamab Mafodotin/Lenalidomide Maintenance Displays Manageable Eye Toxicity Profile in Newly Diagnosed Myeloma

September 20th 2025

Belantamab mafodotin plus lenalidomide maintenance was active and had an expected safety profile in transplant-eligible, newly diagnosed myeloma.

Belantamab Mafodotin Shows Single-Agent Activity in Relapsed/Refractory Multiple Myeloma

September 20th 2025

Belantamab mafodotin monotherapy was active and safe in patients with relapsed/refractory multiple myeloma.

Dr Leleu on QOL Outcomes With SC Isatuximab Via On-Body Delivery in R/R Myeloma

September 20th 2025

Xavier Leleu, MD, PhD, discusses the role of subcutaneous isatuximab delivered via an on-body delivery system in patients with relapsed/refractory multiple myeloma.

ATLAS Analysis Supports KRd After ASCT in High-Risk, Newly Diagnosed Myeloma

September 20th 2025

Carfilzomib, lenalidomide, and dexamethasone after transplant improved PFS and OS in high-risk, newly diagnosed multiple myeloma.

Subcutaneous Isatuximab Delivery Is Noninferior to IV Administration in Multiple Myeloma

September 20th 2025

Efficacy and pharmacokinetic measures with IV vs SC isatuximab delivered via an on-body injector were comparable in patients with multiple myeloma.

Daratumumab/Lenalidomide Maintenance Boosts MRD Negativity in Newly Diagnosed Myeloma

September 20th 2025

Maintenance therapy with daratumumab plus lenalidomide led to higher MRD-negativity conversion rates vs lenalidomide alone in newly diagnosed myeloma.

Dr Anderson on Daratumumab/Lenalidomide Maintenance After ASCT in Newly Diagnosed Myeloma

September 20th 2025

Larry Anderson, MD, PhD, discusses updated efficacy and safety findings of subcutaneous daratumumab plus lenalidomide in newly diagnosed multiple myeloma following autologous stem cell transplant.

Linvoseltamab Yields Favorable Safety Profile and Antimyeloma Activity in High-Risk Smoldering Myeloma

September 19th 2025

Linvoseltamab monotherapy generated responses and had a favorable safety profile with low rates of high-grade TEAEs in high-risk smoldering myeloma.

Belantamab Mafodotin/Bortezomib/Dexamethasone Yields PFS, OS Benefits in Lenalidomide-Refractory Myeloma

September 19th 2025

Treatment with BVd led to favorable survival outcomes and prolonged responses vs DVd in lenalidomide-refractory patients with multiple myeloma.

Daratumumab/Ixazomib Quadruplet Yields Durable Efficacy in Transplant-Ineligible or -Deferred, Newly Diagnosed Myeloma

September 19th 2025

The combination of daratumumab, lenalidomide, ixazomib, and dexamethasone was efficacious in transplant-ineligible, newly diagnosed myeloma.